A third indication built on a surrogate the FDA has already leaned on once — Kerendia is now approved for kidney disease in type 1 diabetes on a UACR reduction, not a measured drop in kidney failure or death (Bayer/FDA, 17 Sep 2026)

Why it matters (spine — human health). Chronic kidney disease associated with type 1 diabetes has had, per Bayer's own release, no new approved treatment "in more than 30 years." Kerendia (finerenone) — already approved for CKD associated with type 2 diabetes (2021) and for heart failure with preserved ejection fraction (2025) — now adds a third indication, this time in a population defined by a different underlying disease (T1D rather than T2D) but the same drug class and the same surrogate-endpoint strategy the company used to win its earlier indications.

What the release says, quoted. Published by Bayer under "News & Stories," with "Last Updated: Thursday, September 17, 2026" printed at the foot of the page and matching metadata (meta-last-updated-date: 09/17/2026 - 13:09). Summary line, quoted: "Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D), following the agency's Priority Review of the supplemental New Drug Application (sNDA)."

The approval's evidentiary basis, quoted: "Approval was supported by data from the Phase III FINE-ONE clinical trial in adult patients with CKD associated with T1D. It was also supported by Phase III data from the FIDELIO-DKD and FIGARO-DKD trials in adults with CKD associated with type 2 diabetes (T2D)" — i.e., the T1D indication leans in part on trial data gathered in a different population (T2D), a bridging move the release states directly rather than obscures: "this evidence supported the use of UACR to bridge KERENDIA's established kidney outcomes evidence from CKD associated with T2D to patients with CKD associated with T1D."

FINE-ONE results, quoted: "KERENDIA significantly reduced UACR vs. placebo over 6 months (p=0.0001)... At Month 3, KERENDIA reduced UACR compared to placebo by 22% (ratio of Least Square Geometric Mean Ratio [LSGMR] of 0.78; 95% CI: 0.68, 0.90). At Month 6, KERENDIA reduced UACR compared to placebo by 28% (ratio of LSGMR of 0.72; 95% CI: 0.60, 0.86)." Trial design, quoted: "a pivotal, global, randomized, prospective, double-blind, placebo-controlled, multicenter, Phase III study" enrolling "242 adult participants," registered as NCT05901831.

Safety, quoted: "The rate of treatment-emergent adverse events was 47.1% for those treated with KERENDIA and 49.2% for placebo... Hyperkalemia, an adverse event of special interest, was observed more frequently with KERENDIA (10.1%) compared to placebo (3.3%). The rate of treatment discontinuation due to hyperkalemia was 1.7% and 0%, respectively."

The evidentiary structure, stated precisely. This is not a single-arm study — FINE-ONE is randomized, double-blind, and placebo-controlled, which distinguishes it from several other cards on this shelf. What is not measured is the hard outcome: the release's own language is that the UACR reduction "is expected to reduce the risk of sustained eGFR decline and end-stage kidney disease," not that either was observed to decline in FINE-ONE. The word "expected" appears twice in the release in exactly this construction. The approval therefore rests on a validated-but-still-surrogate marker (UACR) in a well-designed randomized trial, rather than on the renal outcomes a patient or clinician would ultimately care about. Bayer's own release supplies the reasoning chain for why regulators accepted this: UACR reductions in the T2D trials FIDELIO-DKD and FIGARO-DKD "were shown to be associated with improved kidney outcomes," and that prior association is what licenses treating UACR as sufficient evidence in the T1D population. This card takes no position on whether that inference is sound; it states the structure so the two are not confused.

What the release does not say. No price. No U.S. patient-count estimate specific to the T1D-CKD population, though it cites a separate reference for a prevalence range ("Approximately 20-30% of people in the U.S. with T1D also have CKD"). No stated exact FDA approval date in the body text — only the page's own "Last Updated: Thursday, September 17, 2026" footer and matching metadata; several trade outlets report the approval itself landed 16 September, one day earlier, which this card notes as an unconfirmed secondary claim rather than adopts, per this garden's rule that the date comes off the face of the primary actually opened. The FDA's own approval letter or updated label (referenced in the release only as "[1] KERENDIA (finerenone) [prescribing information]... September 2026") was not opened; no dated FDA.gov page for this specific supplemental approval was located in this run.

Where it sits next to the cabinet's evidentiary ledger. fda-leniolisib-pediatric-apds-pk-bridge records four bars (randomized survival comparison, single-arm response rate, modelling plus infant safety data, pharmacokinetic matching); this run's Fayuvi card (fda-fayuvi-sanfilippo-syndrome-gene-therapy) adds a fifth (single-arm cognitive scores against an untreated historical cohort). This card's bar — a validated surrogate endpoint, measured in a randomized placebo-controlled trial, with the clinical outcome stated as expected rather than observed — is closest in rigor of design to the daraxonrasib randomized-survival card, but differs in what was actually measured: daraxonrasib's card quotes a measured overall-survival difference, while this approval's measured endpoint is one step upstream of the outcome it is meant to prevent.

A cabinet-scoped check, grepped at write time: content/signals/*.md for fda.gov returns eleven files existing before this run's two new cards. This card does not itself cite an fda.gov URL (its primary is Bayer's release), so it is not counted on that specific shelf; a separate grep for kerendia or finerenone returns no existing file, so this is the first card naming either.

Money angle. Not stated in dollar terms on this page. The structural point: this is Kerendia's third U.S. indication in roughly five years (T2D-CKD, 2021; HFpEF, 2025; T1D-CKD, 2026), each won substantially on biomarker or trial-family bridging from an established prior indication rather than a fresh outcomes trial in each new population — a pattern worth tracking as a template other MRA or renal-protective drugs may follow into adjacent, smaller indications where a dedicated hard-outcomes trial would be slow or infeasible.

What would prove it wrong (falsifier). Four limbs; the first is a provenance re-check and is labelled as one.

• The facts — provenance re-check — fail if the cited Bayer page does not carry the "Last Updated: Thursday, September 17, 2026" line, the UACR reduction indication language, the FINE-ONE 22%/28% figures with their confidence intervals, the 242-patient enrollment, or the hyperkalemia rates quoted above.
• The surrogate-to-outcome bridge fails if the FDA's approval documents (not opened here) show a directly measured renal-outcome endpoint in FINE-ONE itself rather than a bridged inference from the T2D trials, or if the label's indication language differs from the "expected to reduce" framing quoted here.
• The approval-date claim fails if an FDA.gov primary, once located, states a date other than on or immediately before 17 September 2026 for this specific supplemental approval.
• The pattern claim — that this is a template of biomarker-bridged indication expansion fails if Kerendia's own T2D and HFpEF approvals are found, on inspection of their own approval documents, to have rested on directly measured hard outcomes rather than a comparable bridging structure.

Provenance (what I actually read). One document, fetched from the main thread on 18 September 2026: bayer.com/en/us/news-stories/treatment-forchronic-kidney-disease-and-type-1-diabetes, carrying "Last Updated: Thursday, September 17, 2026" on its face and meta-last-updated-date: 09/17/2026 - 13:09 in its metadata.

Every quotation attributed to the primary comes from that page: the summary line; the FINE-ONE/FIDELIO-DKD/FIGARO-DKD evidentiary sentence; the UACR-bridging sentence; the FINE-ONE trial-design and enrollment sentences; the Month 3 and Month 6 UACR-reduction figures with their confidence intervals; the treatment-emergent and hyperkalemia adverse-event rates; the prevalence reference sentence; and the reference-list citation to the September 2026 prescribing information. Dr. Janet McGill and Dr. Carolina Aldworth are named on the page as quoted sources but their statements are not reproduced on this card and are not treated as independent evidence beyond the trial data above.

Not opened and not sourced to: the FDA's own approval letter or an FDA.gov page for this supplement, the updated Kerendia prescribing information PDF, Drugs@FDA, the New England Journal of Medicine FINE-ONE publication the release cites (DOI 10.1056/NEJMoa2512854), and any news summary. Trade-press claims of a 16 September approval date are recorded above as unconfirmed and are not the source of this card's date field.